The committee received 1475 written submissions, including a submission from Painaustralia.
Painaustralia’s submission outlined the need for Australians with chronic pain to access the best possible treatment options and care for their pain, as determined with their clinician. This may include medicinal cannabis if a clinician, together with their patient, believes it will provide benefit. Further clinical research is needed to establish an evidence base for the use of medicinal cannabis across the spectrum of pain conditions.
Medicinal Cannabis is produced from an extract of the cannabis plant. Cannabis contains chemicals called cannabinoids, which are shown to relieve symptoms of disease. These cannabinoids act on receptors within our brain and other parts of the body by mimicking naturally occurring cannabinoids (called ‘endocannabinoids’).
Medicinal cannabis is emerging as a possible treatment option for chronic pain and there is substantial anecdotal evidence from patients who have benefitted from this treatment.